Qualigen Therapeutics, Inc.

As of October 15, 2023, Qualigen Therapeutics, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5 and a price-to-book ratio of 1.8, indicating a solid balance sheet and favorable comparison to peers like Bio-Rad Laboratories and Thermo Fisher Scientific.

As of October 1, 2023, there is insufficient technical data to assess the current stance of Qualigen Therapeutics, Inc.

As of March 2022, the management team of Qualigen Therapeutics, Inc. includes Michael Poirier (Chairman, CEO), Amy Broidrick (Executive VP, Chief Strategy Officer), and several independent directors: Ira Ritter, Richard David, Sidney Emery, Matthew Korenberg, and Kurt Kruger. They oversee the company's strategic direction and operations.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing cancer and infectious disease treatments and its FastPack diagnostic platform. It has a market cap of $2.58 million and reported a net profit loss of $2 million as of September 2024.

As of Jun 18, Qualigen Therapeutics, Inc. has a market capitalization of 2.58 million, with net sales of 0.00 million and a net profit of -7.77 million over the last four quarters. The company's shareholder's funds were -2.10 million, and total assets were 2.03 million as of Dec 23.